Major players operating in the global hepatitis drugs market are focused on approval and launch of new products to expand their product portfolio. For instance, in 2018, Natco Pharma launched Hepcinat Plus, a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C in India.
The global hepatitis drugs market size was valued at US$ 21,848.3 million in 2019, and is expected to witness a CAGR of 4.1% over the forecast period (2021 – 2028).
Get PDF Sample Copy of this report @
https://www.coherentmarketinsights.com/insight/request-sample/2977
High prevalence of hepatitis is expected to propel growth of the global hepatitis drugs market over the forecast period. For instance, in May 2019, according to the study, ‘Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda’, published in May 2019, in BMC Infectious Diseases, the prevalence of hepatitis B surface antigen was 3.9% in the study population.
Initiatives to boost treatment and management of hepatitis is expected to offer lucrative growth opportunities for players in the global hepatitis drugs market. For instance, in 2017, the U.S. Department of Health And Human Service started the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) for the treatment and management of hepatitis in the US.
Market Trends
The market is witnessing increasing demand for generic drugs. For instance in 2015, Gilead licensed its hepatitis C drug Sovaldi to seven generic drug manufacturers companies in India to make and sell a low-cost version of the medicine in 91 emerging economies.
The market is also witnessing approval and launch of new products. For instance, in 2016, The U.S. Food and Drug Administration approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2977
High cost of manufacturing hepatitis drugs is due to high expenses incurred to procure raw materials such as active pharmaceutical ingredients (APIs) and drug intermediates is expected to limit growth of the global hepatitis drugs market.
Major players operating in the global hepatitis drugs market include, AbbVie Inc., Bristol Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC., Hetero Healthcare Limited, LAURUS Labs, Merck & Co. Inc., and Zydus Cadila.
Reasons to Buy this Hepatitis Drugs Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Hepatitis Drugs market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Hepatitis Drugs market
➡Leading company profiles reveal details of key Hepatitis Drugs market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Hepatitis Drugs market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat 30% Off @ https://www.coherentmarketinsights.com/promo/buynow/2977
Table of Content
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Landscape
- Epidemiology Analysis
- Reimbursement Scenario
- PEST Analysis
- Market Dynamics
- Global Hepatitis Drugs Market, By Drug Class, 2019 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Interferon Alphas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- HIV NRTIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Hepatitis C Protease / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleotide Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleoside Analogue Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Thrombopoiesis Stimulating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- Global Hepatitis Drugs Market, By Disease Type, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- Global Hepatitis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- Global Hepatitis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- Global Hepatitis Drugs Market, By Region, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)l
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LAURUS Labs
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hetero Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline PLC.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cipla Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co. Inc.
- Analyst Views
- Company Profiles
- Section
- References
- Research Methodology
- About Us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837